Related Experiment Video
Updated: Jun 14, 2025
08:30
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
Published on: March 12, 2016
13.0K
Nicotinamide: Bright Potential in Glaucoma Management.
Silvia Babighian1, Irene Gattazzo1, Maria Sole Zanella1
1Department of Ophthalmology, Ospedale Sant'Antonio, Azienda Ospedaliera, 35127 Padova, Italy.
Biomedicines
|August 29, 2024
Summary
Nicotinamide shows promise for glaucoma treatment by protecting the optic nerve and potentially lowering intraocular pressure (IOP). Further research is needed to confirm its efficacy and safety in patients.
Area of Science:
- Ophthalmology
- Neuroscience
- Nutritional Science
Background:
- Glaucoma presents significant management challenges due to limited treatments and adverse effects.
- Nicotinamide, a nutrient, offers potential neuroprotection and intraocular pressure (IOP) modulation for glaucoma.
Purpose of the Study:
- To review current literature on nicotinamide for glaucoma management.
- To analyze nicotinamide's mechanisms, efficacy, and safety in glaucoma.
Main Methods:
- Systematic PubMed search for nicotinamide's therapeutic actions in ocular hypertension and glaucoma.
- Included studies evaluating effects on retinal ganglion cells (RGCs), optic nerve, IOP, and neuroinflammation.
Main Results:
- Preclinical evidence shows nicotinamide protects RGCs and optic nerve integrity.
- Nicotinamide may reduce glaucoma-associated neuroinflammation and modulate IOP via ocular blood flow and aqueous humor dynamics.
Conclusions:
- Nicotinamide is a promising therapeutic for glaucoma, offering neuroprotection and IOP reduction.
- Further research is recommended to establish efficacy, safe dosing, and long-term safety in glaucoma patients.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
408
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
408
01:28Angle Closure Glaucoma: Treatment
454
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
454
01:25Glaucoma: Overview
528
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
528
01:23Drugs Acting on Autonomic Ganglia: Stimulants
1.3K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.3K
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.2K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.2K
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
704
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
704